v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities:    
Net income (loss) $ 113,445 $ (18,921)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Stock-based compensation 20,457 18,355
Depreciation and amortization 6,710 7,322
Amortization of right-of-use assets 2,656 2,671
Loss on disposal of asset 210 0
Gain on sale of lab products business (112,966) 0
Revaluation of contingent consideration to estimated fair value 0 547
Amortization of premium and accretion of discount on marketable securities, net 1,414 562
Other 66 (7)
Changes in operating assets and liabilities:    
Accounts receivable (38) (2,336)
Inventory 1,926 (6,741)
Prepaid and other assets (8,379) (4,170)
Operating leases liabilities, net (2,963) (2,953)
Accounts payable 859 1,625
Accrued compensation (621) (19,303)
Accrued and other liabilities 11,218 5,544
Deferred revenue 943 1,116
Net cash provided by (used in) operating activities 34,937 (16,689)
Investing activities:    
Purchases of marketable securities (39,850) (67,280)
Maturities of marketable securities 59,744 94,639
Sales of marketable securities 114,636 0
Purchase of long term investment (2,000) 0
Proceeds from sale of lab products business, net 164,792 0
Additions of property and equipment (5,677) (2,637)
Net cash provided by investing activities 291,645 24,722
Financing activities:    
Proceeds from issuance of common stock under employee stock purchase plan 2,497 2,272
Taxes paid related to net share settlement of restricted stock units (8,528) (9,304)
Proceeds from exercise of stock options 1,354 4,078
Payment of contingent consideration (1,500) (1,500)
Repurchase and retirement of common stock (12,232) (50,000)
Net cash used in financing activities (18,409) (54,454)
Effect of exchange rate changes on cash and cash equivalents 4 (90)
Net increase (decrease) in cash, cash equivalents and restricted cash 308,177 (46,511)
Cash, cash equivalents and restricted cash at beginning of period 65,980 115,274
Cash, cash equivalents and restricted cash at end of period $ 374,157 $ 68,763